Login to Your Account



Arpida's Iclaprim Jumps Over Hurdle, Hits In Phase III Study

By Cormac Sheridan


Wednesday, December 6, 2006
Arpida Ltd. remains on track to file a new drug application in 2007 for its lead compound, iclaprim, which attained the primary endpoint in the first of two Phase III clinical trials by demonstrating statistical non-inferiority to linezolid (Zyvox) in the treatment of complicated skin and skin-structure infection (CSSSi). (BioWorld International)

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription